InMed Historical Balance Sheet

INM Stock  USD 5.26  0.11  2.14%   
Trend analysis of InMed Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 9.7 M or Property Plant And Equipment Net of 1.3 M provides information on InMed Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of InMed Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using InMed Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining InMed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether InMed Pharmaceuticals is a good buy for the upcoming year.

InMed Pharmaceuticals Inventory

1.31 Million

  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

About InMed Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of InMed Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. InMed Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of InMed Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which InMed currently owns. An asset can also be divided into two categories, current and non-current.

InMed Pharmaceuticals Balance Sheet Chart

At this time, InMed Pharmaceuticals' Common Stock Shares Outstanding is very stable compared to the past year. As of the 15th of December 2024, Short Term Investments is likely to grow to about 45.2 M, though Net Debt is likely to grow to (5.3 M).

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.
Most accounts from InMed Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Common Stock Shares Outstanding is very stable compared to the past year. As of the 15th of December 2024, Short Term Investments is likely to grow to about 45.2 M, though Net Debt is likely to grow to (5.3 M).
 2021 2022 2023 2024 (projected)
Total Current Liabilities3.3M2.0M2.0M1.1M
Total Assets12.8M14.1M11.8M12.4M

InMed Pharmaceuticals balance sheet Correlations

0.60.990.2-0.93-0.580.760.920.31-0.110.920.40.340.380.67-0.07-0.26-0.240.60.990.20.360.51-0.330.430.09
0.60.470.35-0.4-0.80.80.450.58-0.10.390.360.30.30.22-0.32-0.270.180.940.520.440.490.88-0.760.760.18
0.990.470.13-0.96-0.460.690.950.19-0.10.960.330.260.320.68-0.03-0.25-0.320.460.990.110.260.39-0.240.330.08
0.20.350.130.08-0.320.28-0.090.750.77-0.050.690.490.450.270.07-0.090.390.450.09-0.090.320.17-0.120.4-0.73
-0.93-0.4-0.960.080.37-0.63-0.990.010.25-0.98-0.14-0.13-0.18-0.560.130.210.43-0.36-0.97-0.07-0.14-0.350.23-0.19-0.23
-0.58-0.8-0.46-0.320.37-0.52-0.37-0.750.32-0.29-0.72-0.75-0.76-0.210.170.39-0.41-0.9-0.49-0.74-0.81-0.670.55-0.8-0.28
0.760.80.690.28-0.63-0.520.640.270.010.670.220.150.090.66-0.18-0.02-0.330.750.740.040.290.86-0.40.380.01
0.920.450.95-0.09-0.99-0.370.64-0.01-0.250.980.110.090.150.53-0.14-0.22-0.430.370.960.070.120.38-0.270.230.28
0.310.580.190.750.01-0.750.27-0.010.23-0.050.830.740.730.120.12-0.310.670.730.170.590.760.33-0.390.82-0.24
-0.11-0.1-0.10.770.250.320.01-0.250.23-0.150.17-0.09-0.080.130.080.050.11-0.12-0.16-0.6-0.31-0.20.1-0.1-0.91
0.920.390.96-0.05-0.98-0.290.670.98-0.05-0.150.10.050.110.64-0.1-0.17-0.50.320.97-0.040.050.38-0.190.160.18
0.40.360.330.69-0.14-0.720.220.110.830.170.10.920.940.340.21-0.350.470.560.290.420.730.22-0.070.6-0.22
0.340.30.260.49-0.13-0.750.150.090.74-0.090.050.920.90.320.11-0.120.450.560.240.530.860.190.040.49-0.01
0.380.30.320.45-0.18-0.760.090.150.73-0.080.110.940.90.170.16-0.540.490.490.280.570.680.19-0.140.610.01
0.670.220.680.27-0.56-0.210.660.530.120.130.640.340.320.170.130.28-0.390.30.67-0.160.30.340.240.02-0.16
-0.07-0.32-0.030.070.130.17-0.18-0.140.120.08-0.10.210.110.160.13-0.07-0.14-0.26-0.090.10.16-0.290.530.13-0.08
-0.26-0.27-0.25-0.090.210.39-0.02-0.22-0.310.05-0.17-0.35-0.12-0.540.28-0.07-0.27-0.17-0.22-0.350.03-0.180.53-0.54-0.08
-0.240.18-0.320.390.43-0.41-0.33-0.430.670.11-0.50.470.450.49-0.39-0.14-0.270.28-0.340.550.45-0.1-0.40.53-0.11
0.60.940.460.45-0.36-0.90.750.370.73-0.120.320.560.560.490.3-0.26-0.170.280.50.530.710.82-0.620.740.09
0.990.520.990.09-0.97-0.490.740.960.17-0.160.970.290.240.280.67-0.09-0.22-0.340.50.140.270.47-0.290.330.14
0.20.440.11-0.09-0.07-0.740.040.070.59-0.6-0.040.420.530.57-0.160.1-0.350.550.530.140.760.28-0.430.740.53
0.360.490.260.32-0.14-0.810.290.120.76-0.310.050.730.860.680.30.160.030.450.710.270.760.35-0.120.650.22
0.510.880.390.17-0.35-0.670.860.380.33-0.20.380.220.190.190.34-0.29-0.18-0.10.820.470.280.35-0.570.520.24
-0.33-0.76-0.24-0.120.230.55-0.4-0.27-0.390.1-0.19-0.070.04-0.140.240.530.53-0.4-0.62-0.29-0.43-0.12-0.57-0.64-0.15
0.430.760.330.4-0.19-0.80.380.230.82-0.10.160.60.490.610.020.13-0.540.530.740.330.740.650.52-0.640.2
0.090.180.08-0.73-0.23-0.280.010.28-0.24-0.910.18-0.22-0.010.01-0.16-0.08-0.08-0.110.090.140.530.220.24-0.150.2
Click cells to compare fundamentals

InMed Pharmaceuticals Account Relationship Matchups

InMed Pharmaceuticals balance sheet Accounts

201920202021202220232024 (projected)
Total Assets7.5M9.8M12.8M14.1M11.8M12.4M
Total Current Liabilities1.7M2.2M3.3M2.0M2.0M1.1M
Total Stockholder Equity5.6M7.4M9.1M12.1M9.2M9.7M
Property Plant And Equipment Net402.6K326.6K904.3K723.4K1.2M1.3M
Net Debt(5.5M)(7.1M)(5.4M)(8.5M)(5.6M)(5.3M)
Retained Earnings(56.0M)(74.9M)(93.5M)(101.4M)(109.1M)(103.6M)
Accounts Payable959.2K775.1K1.2M544.2K626.2K615.9K
Cash5.8M7.4M6.2M8.9M6.6M3.4M
Non Current Assets Total1.2M1.4M3.2M2.8M3.1M3.3M
Cash And Short Term Investments5.8M7.4M6.2M8.9M6.6M3.9M
Net Receivables45.2K11.9K88.0K260.4K352.8K370.5K
Common Stock Shares Outstanding208.8K270K560.8K2.4M7.6M8.0M
Short Term Investments42.3K46.5K44.8K44.4M43.1M45.2M
Liabilities And Stockholders Equity7.5M9.8M12.8M14.1M11.8M12.4M
Non Current Liabilities Total247.5K189.3K389.5K16.0K644.9K677.1K
Inventory(919.56)(955.8M)2.5M1.6M1.2M1.3M
Other Current Assets418.9K956.8K842.0K(8.9B)477.7K501.6K
Other Stockholder Equity(59.5M)21.5M31.7M35.7M35.4M37.1M
Total Liab1.9M2.4M3.7M2.0M2.6M2.7M
Total Current Assets6.3M8.4M9.6M11.3M8.7M9.1M
Accumulated Other Comprehensive Income59.6M63.4M70.8M128.6K147.9K140.5K
Intangible Assets799.3K1.1M2.1M1.9M1.8M1.9M
Common Stock50.2M60.6M70.7M77.6M82.8M53.5M
Net Tangible Assets6.5M6.3M7.0M10.1M9.1M9.1M
Net Invested Capital5.6M7.4M9.1M12.1M9.2M8.4M
Net Working Capital4.6M6.2M6.3M9.3M6.7M7.1M
Property Plant Equipment549.9K326.6K904.3K723.4K831.9K873.5K
Capital Stock50.2M60.6M70.7M77.6M82.8M72.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
230.4
Revenue Per Share
0.603
Quarterly Revenue Growth
(0.45)
Return On Assets
(0.39)
Return On Equity
(0.72)
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.